Literature DB >> 26274600

Advances in Antibody Design.

Kathryn E Tiller1, Peter M Tessier1.   

Abstract

The use of monoclonal antibodies as therapeutics requires optimizing several of their key attributes. These include binding affinity and specificity, folding stability, solubility, pharmacokinetics, effector functions, and compatibility with the attachment of additional antibody domains (bispecific antibodies) and cytotoxic drugs (antibody-drug conjugates). Addressing these and other challenges requires the use of systematic design methods that complement powerful immunization and in vitro screening methods. We review advances in designing the binding loops, scaffolds, domain interfaces, constant regions, post-translational and chemical modifications, and bispecific architectures of antibodies and fragments thereof to improve their bioactivity. We also highlight unmet challenges in antibody design that must be overcome to generate potent antibody therapeutics.

Entities:  

Keywords:  CDR; Fab; IgG; VH; complementarity-determining region; scFv

Mesh:

Substances:

Year:  2015        PMID: 26274600      PMCID: PMC5289076          DOI: 10.1146/annurev-bioeng-071114-040733

Source DB:  PubMed          Journal:  Annu Rev Biomed Eng        ISSN: 1523-9829            Impact factor:   9.590


  150 in total

1.  OptCDR: a general computational method for the design of antibody complementarity determining regions for targeted epitope binding.

Authors:  R J Pantazes; C D Maranas
Journal:  Protein Eng Des Sel       Date:  2010-09-16       Impact factor: 1.650

Review 2.  Macromolecular modeling with rosetta.

Authors:  Rhiju Das; David Baker
Journal:  Annu Rev Biochem       Date:  2008       Impact factor: 23.643

3.  High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site.

Authors:  C F Barbas; L R Languino; J W Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

4.  Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis.

Authors:  R Blake Pepinsky; Laura Silvian; Steven A Berkowitz; Graham Farrington; Alexey Lugovskoy; Lee Walus; John Eldredge; Allan Capili; Sha Mi; Christilyn Graff; Ellen Garber
Journal:  Protein Sci       Date:  2010-05       Impact factor: 6.725

5.  Ab initio structure prediction of the antibody hypervariable H3 loop.

Authors:  Kai Zhu; Tyler Day
Journal:  Proteins       Date:  2013-05-02

6.  Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.

Authors:  Joseph M Perchiacca; Ali Reza A Ladiwala; Moumita Bhattacharya; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2012-07-27       Impact factor: 1.650

7.  A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.

Authors:  Jaafar N Haidar; Qing-An Yuan; Lin Zeng; Mark Snavely; Xenia Luna; Haifan Zhang; Wei Zhu; Dale L Ludwig; Zhenping Zhu
Journal:  Proteins       Date:  2011-12-16

8.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

9.  GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Authors:  Christian A Gerdes; Valeria Gonzalez Nicolini; Sylvia Herter; Erwin van Puijenbroek; Sabine Lang; Michaela Roemmele; Ekkehard Moessner; Olivier Freytag; Thomas Friess; Carola H Ries; Birgit Bossenmaier; Hans Joachim Mueller; Pablo Umaña
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

Review 10.  Potent antibody drug conjugates for cancer therapy.

Authors:  Peter D Senter
Journal:  Curr Opin Chem Biol       Date:  2009-05-04       Impact factor: 8.822

View more
  68 in total

Review 1.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

2.  Direct single-molecule imaging for diagnostic and blood screening assays.

Authors:  Qiaoqiao Ruan; Patrick J Macdonald; Kerry M Swift; Sergey Y Tetin
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 3.  AChiralPentagonalPolyhedralFramework forCharacterizingVirusCapsidStructures.

Authors:  Aditya Raguram; V Sasisekharan; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2017-01-13       Impact factor: 17.079

4.  Improving the Accuracy of Protein Thermostability Predictions for Single Point Mutations.

Authors:  Jianxin Duan; Dmitry Lupyan; Lingle Wang
Journal:  Biophys J       Date:  2020-05-29       Impact factor: 4.033

5.  Ultraviolet Photodissociation Mass Spectrometry for Analysis of Biological Molecules.

Authors:  Jennifer S Brodbelt; Lindsay J Morrison; Inês Santos
Journal:  Chem Rev       Date:  2019-12-18       Impact factor: 60.622

6.  Physicochemical Rules for Identifying Monoclonal Antibodies with Drug-like Specificity.

Authors:  Yulei Zhang; Lina Wu; Priyanka Gupta; Alec A Desai; Matthew D Smith; Lilia A Rabia; Seth D Ludwig; Peter M Tessier
Journal:  Mol Pharm       Date:  2020-06-11       Impact factor: 4.939

Review 7.  Selecting and engineering monoclonal antibodies with drug-like specificity.

Authors:  Charles G Starr; Peter M Tessier
Journal:  Curr Opin Biotechnol       Date:  2019-02-26       Impact factor: 9.740

Review 8.  Leukemic stem cells: identification and clinical application.

Authors:  Diana Hanekamp; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Int J Hematol       Date:  2017-03-29       Impact factor: 2.490

9.  Computational de novo design of antibodies binding to a peptide with high affinity.

Authors:  Venkata Giridhar Poosarla; Tong Li; Boon Chong Goh; Klaus Schulten; Thomas K Wood; Costas D Maranas
Journal:  Biotechnol Bioeng       Date:  2017-02-02       Impact factor: 4.530

Review 10.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.